469 Treffer:
41.
Comprehensive assessment of clinical features and biomarkers to identify patients with advanced or metastatic breast cancer for marker driven trials in humans (CATCH).
NCT Heidelberg » Ihre Suche
Datum: 2025-10-23
42.
Comprehensive assesment of clinical features, genomics and further molecular marker to identify patients with early breast cancer for enrolment on marker driven trials
NCT Heidelberg » Ihre Suche
Datum: 2025-10-23
43.
CAPTOR-BC: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
NCT Heidelberg » Ihre Suche
Datum: 2025-10-23
44.
A Randomized, Open-label, Phase II Trial Comparing Neoadjuvant Endocrine Therapy in Combination With Trastuzumab, Pertuzumab +/- the PI3K Inhibitor Inavolisib in Patients With HER2-positive, HR-positive, PIK3CA Mutant Early Breast Cancer-GeparPiPPa
NCT Heidelberg » Ihre Suche
Datum: 2025-10-23
45.
Sequential Gilteritinib in Combination With Venetoclax and Azacitidine for Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and FLT3 Mutations Ineligible for Intensive Treatment.
NCT Heidelberg » Ihre Suche
Datum: 2025-10-23
46.
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)
NCT Heidelberg » Ihre Suche
Datum: 2025-10-23
47.
Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induc
NCT Heidelberg » Ihre Suche
Datum: 2025-10-23
48.
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
NCT Heidelberg » Ihre Suche
Datum: 2025-10-23
49.
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing CC-92480 (BMS-986348), Carfilzomib, and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT Heidelberg » Ihre Suche
Datum: 2025-10-23
50.
A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator's Choice of Therapy in Second- or Later-Line Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenoca
NCT Heidelberg » Ihre Suche
Datum: 2025-10-23